financial

Key Takeaways Novo Nordisk leads the GLP-1 market but faces rising competition and a weaker 2026 sales and…

Key Takeaways NVO’s Ozempic and Wegovy drove 67% of total 2025 sales, making their Q1 performance central to…

Novo Nordisk braces for a major 2026 profit drop amid US pricing pressure, while investing in AI drug…

Novo Nordisk braces for a major 2026 profit drop amid US pricing pressure, while investing in AI drug…

For Immediate Release Chicago, IL – April 16, 2026 – Zacks.com announces the list of stocks featured in…

Wednesday, April 15, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today’s…

Key Takeaways Eli Lilly’s Foundayo approval introduces a direct oral GLP-1 rival to Novo Nordisk’s Wegovy pill.LLY’s strong…

Key Takeaways NVO stock dropped 36% in 3 months due to a weak 2026 outlook and rising competition…

Novo Nordisk launches high-dose & oral Wegovy in the US and eases EU cold-chain rules to compete with…

The consolidated revenue of Vilniaus baldai AB and its subsidiaries (the “Group”) for the six-month period of the…

Key Takeaways Novo Nordisk and its partner reported phase II data for UBT251 in Chinese patients with type…

Key Takeaways Novo Nordisk leads the GLP-1 market but faces slowing demand, pricing pressure and rising competition.GPCR reports…

Novo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet? – April 27, 2026